UNITED THERAPEUTICS Corp

Nasdaq: UTHR·Silver Spring, Maryland·

Price
$587.88
Base IV
$438.71

Valuation snapshot

Above base case

At $587.88, the price sits between our base case ($438.71) and bull case ($683.84).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$438.71
75% of the price · range $253.22–$683.84
Price vs base case
34% above
$587.88 against $438.71
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $253.22 to bull $683.84. Values per share.

Price against each value

Bear case
$253.22
Price 132% above
No growth
…
—
Base case
$438.71
Price 34% above
Researched byClaude Opus 5.5
Valuation Nov 13, 2026 · Price as of Nov 16, 2026How we got here

What does United Therapeutics do?

United Therapeutics provides pharmaceutical therapies and technologies to treat pulmonary arterial hypertension and other rare diseases, while developing methods to increase the availability of transplantable organs.

It brought in $3.2B of sales in the 12 months to Sep 2026.

Led by Martine Rothblatt, Founder, Chairperson and Chief Executive Officer since 1996. United Therapeutics Corp Form 10-K for fiscal year 2025 (Information About Our Executive Officers)

Industry
Healthcare
Based in
Silver Spring, Maryland
Trades on
Nasdaq as UTHR

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 39¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 23¢ of every dollar.

  • Making what it sells14¢
  • Research and development22¢
  • Sales, marketing and admin23¢
  • Tax9¢
  • Left as profit39¢
  • Interest and other income came back in+6¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays United Therapeutics, and for what?

United Therapeutics is a biotechnology company that develops and sells prescription medicines for rare, life-threatening lung conditions, primarily pulmonary arterial hypertension, and high-risk pediatric cancer. It also develops bioengineered organ transplant technologies to address donor organ shortages.

The company sells its medicines primarily to specialized pharmaceutical distributors, who deliver them to pharmacies, hospitals, and patients.

  • Tyvaso DPI

    41%

    An inhaled dry powder medicine taken with a pocket-sized inhaler to treat high blood pressure in lung arteries and lung tissue scarring.

  • Nebulized Tyvaso

    18%

    An inhaled liquid solution administered via an ultrasonic nebulizer device to treat pulmonary hypertension and interstitial lung disease.

  • Remodulin

    17%

    A continuously infused drug administered intravenously or under the skin via specialized external pumps to treat pulmonary arterial hypertension.

  • Orenitram

    16%

    An extended-release oral tablet taken to delay disease progression and improve exercise capacity in patients with pulmonary arterial hypertension.

  • Unituxin

    7%

    An antibody injection used in hospitals to treat pediatric patients with high-risk neuroblastoma, a rare nerve cell cancer.

  • Adcirca

    1%

    A daily oral tablet licensed from Eli Lilly that helps relax pulmonary blood vessels to improve exercise ability in PAH patients.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Research Triangle Park Campus — Research Triangle Park, United States. This 279-acre co-headquarters campus synthesizes treprostinil, the active ingredient in Tyvaso DPI, Nebulized Tyvaso and Remodulin, makes Orenitram drug product and packages and distributes the commercial portfolio, so it underpins nearly all of the company's revenue.
  • Griffith and Montgomery Xenograft Production Facility — Houston, United States. Opened in October 2026 as the company's third Designated Pathogen-Free facility, it is purpose-built to make xenokidneys and xenohearts and is intended to help scale commercial production if the still-investigational xeno-organs are approved.
  • Thomas E. Starzl Xenograft Production Facility — Stewartville, United States. Opened on August 12, 2026 as the company's second Designated Pathogen-Free facility, this site is the other half of the planned capacity for scaling commercial xeno-organ production if approval is obtained.
  • Christiansburg DPF Facility — Christiansburg, United States. This owned 65,000 square foot clinical-scale facility, completed in February 2024, produces the porcine organs used in xenotransplantation trials, with capacity of about 125 organs per year supplying the UKidney clinical program.
  • Jacksonville EVLP Center — Jacksonville, United States. This owned 75,000 square foot building on the Mayo Clinic campus is one of two sites from which Lung Bioengineering provides commercial fee-for-service ex vivo lung perfusion to transplant centers, giving the company a revenue-generating organ-services foothold.
See them on the globe

United Therapeutics 2025 Form 10-K

How is the business doing?

Sales grew from $1.5B in 2020 to $3.2B in 2025, about 16% a year.

Running the business leaves about 41¢ of each sales dollar as operating profit, about the same as 40¢ in 2020.

After paying for its upkeep and new investment, it had $867.2M of cash to spare in the 12 months to Sep 2026.

Sales$3.2B
20162025
Operating margin47%
20162025
Free cash flow$1B
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

United Therapeutics exists to discover and deliver novel treatments for severe rare diseases and develop engineered technologies that create an unlimited supply of transplantable human organs.

“provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.”

United Therapeutics Public Benefit Purpose

Who is responsible for the plan?

Roles checked November 13, 2026.

What management says it is working on now:

  • Expand Tyvaso Prescriptions

    Growing sales of Tyvaso DPI and increasing the number of patients treated for pulmonary hypertension linked with interstitial lung disease.

    United Therapeutics 2025 Form 10-K
  • Advance Late-Stage Lung Pipeline

    Seeking regulatory approval to expand Nebulized Tyvaso into idiopathic pulmonary fibrosis and progressive pulmonary fibrosis following Phase 3 trials.

    United Therapeutics 2025 Form 10-K
  • Progress Gene-Edited Organ Trials

    Advancing clinical trials for gene-edited pig kidneys and hearts (UKidney and UThymoKidney) to solve human donor organ shortages.

    United Therapeutics 2025 Form 10-K
  • Construct Manufacturing Infrastructure

    Investing approximately $400 million through 2028 to build new pharmaceutical production and pathogen-free animal facilities in North Carolina, Minnesota, and Texas.

    United Therapeutics 2025 Form 10-K
Annualized revenue run rate, by the end of 2027
$4 billion
United Therapeutics Q4 2025 Earnings Call
Capital expenditures, during 2026 through 2028
approximately $400 million
United Therapeutics 2025 Form 10-K
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 4% more than a year earlier. The year before, quarters averaged 3%.

Its operating margin is narrower than a year ago: 37¢ per sales dollar, against 49¢.

The share price is about where it was in Oct 2026, near $587.88.

Bull $683.84Base $438.71Bear $253.22Oct 30Nov 16 · $587.88
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • late Q1 or early Q2 2026

    TETON 1 Phase 3 Data Readout

    Topline clinical trial results for Nebulized Tyvaso in patients with idiopathic pulmonary fibrosis across the US and Canada.

    United Therapeutics 2025 Form 10-K
  • late Q1 or early Q2 2026

    Ralinepag ADVANCE OUTCOMES Phase 3 Data

    Topline study data evaluating once-daily oral ralinepag to delay clinical worsening in patients with pulmonary arterial hypertension.

    United Therapeutics 2025 Form 10-K
  • December 31, 2026

    Adcirca License Agreement Expiration

    The commercial licensing agreement with Eli Lilly granting United Therapeutics rights to market Adcirca in the US expires.

    United Therapeutics 2025 Form 10-K

Our own estimate moved too: the base case went from $462.70 to $438.71 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Heavy Reliance on Treprostinil Products

    Over 90% of revenue comes from treprostinil therapies. Any drop in demand, pricing pressure, or manufacturing disruption would heavily harm financial results.

    From the company's own filingsWould hit how fast sales growUnited Therapeutics 2025 Form 10-K

  2. Intense Brand and Generic Competition

    New competing brand drugs like Winrevair and Yutrepia, along with cheaper generic options, could take away market share and force price cuts.

    From the company's own filingsWould hit how fast sales growUnited Therapeutics 2025 Form 10-K

  3. Single-Source Third-Party Manufacturers and Devices

    The company relies on single suppliers for key products, such as MannKind for Tyvaso DPI and DEKA for Remunity pumps, leaving it vulnerable to production delays.

    From the company's own filingsWould hit how much of each sale it keepsUnited Therapeutics 2025 Form 10-K

  4. Reimbursement and Healthcare Price Pressures

    Because therapies are expensive, policy reforms like the Inflation Reduction Act or insurer restrictions could limit pricing and patient coverage.

    From the company's own filingsWould hit how fast sales growUnited Therapeutics 2025 Form 10-K

  5. Clinical Trial and Regulatory Uncertainty

    Future growth requires success in late-stage clinical trials and regulatory reviews; failed trials or delayed approvals prevent commercialization.

    From the company's own filingsWould hit how much it has to reinvestUnited Therapeutics 2025 Form 10-K

  6. Distributor Concentration

    In the United States, almost all treprostinil product revenue comes through just two specialty distributors, Accredo and CVS Specialty.

    From the company's own filingsWould hit how fast sales growUnited Therapeutics 2025 Form 10-K

  7. Overall survival at week 52 favored Tyvaso but was not statistically significant, which could temper payer and physician adoption.

    From our researchWould hit how fast sales growUTHR 10-Q Q3 2026

  8. Adjusted operating margin fell 11.6 points year over year to 41.9% in Q3 2026, with expenses growing faster than revenue.

    From our researchWould hit how much of each sale it keepsStockStory Q3 2026 results

Is it a good business?

From 2024 to 2025 it earned between 28% and 31% on the capital invested in it, a median of 29%. Its cost of capital in the latest valuation is 8.1%; returns were above it in every one of the 2 years.

From 2016 to 2025 it earned between -4% and 39% on its shareholders' equity, a median of 18%.

Over 10 years its operating margin ranged from 13¢ to 66¢ per sales dollar, a median of 48¢. Gross margin ran from 88¢ to 95¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital28%
20162025

Cost of capital 8.1%

Return on equity19%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 22%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 4.2% in a year, so each remaining share owns a slightly bigger slice.

It holds $2.1B more in cash than it owes.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $587.88. Our put its value between $253.22 and $683.84, with $438.71 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $253.22

This scenario assumes United Therapeutics' sales stay roughly as flat as they were over the past year, its new lung-scarring treatment catches on slowly, and competitors and rising costs keep profits below the levels of 2024-2025.

Base case, $438.71

This scenario assumes sales, which were roughly flat over the past year, return to solid growth once the company's lung treatment wins approval for a new lung-scarring disease, while profits stay close to their recent high levels.

Bull case, $683.84

This scenario assumes United Therapeutics breaks out of its recent flat year as its lung treatment quickly becomes a widely used therapy for a new lung-scarring disease, pushing sales up strongly and profits back to the very high levels of 2024-2025.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects more than we do.Price above value: 34%

For United Therapeutics to be worth today's $587.88, sales would need to grow about 16.6% a year. We assume 8.6%. Over the last 5 years, sales grew 14.0% a year.

−5%0%+5%+10%+15%+20%We assume 8.6%Past 5 yrs 14.0%Price needs 16.6%

Or, if sales grow 8.6% as we assume, the price works with a profit margin of 59.3% (we assume 43.0%).

Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.

Do you think sales can grow 16.6% a year?

Try your own numbers

We're moderately sure of this range: it scores 65 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $438.71 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average8.6%
  • Operating margin43.0%
  • Long-term growth rate2.0%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$438.71 -25.4%

Build